ArticleFrontiers in pharmacology2024

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System.

Dongdong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.